AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

EBS · NYSE · Drug Manufacturers - Specialty & Generic

Emergent BioSolutions (EBS)

Supplies naloxone sprays and government-procured medical countermeasures for public-health emergencies.

$6.86

After hours+0.11 (+1.63%)

At close$6.75(+3.05%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	271	277	300	255	294	195	222	141	231	149	156	234
Cost of revenue	178	107	160	320	130	58	106	83	102	102	89	97
Gross profit	92	169	141	−66	164	137	117	58	129	47	68	137
	335	213	101	138	100	146	68	57	52	63	57	262
Research & development	15	29	15	33	14	9	15	13	14	12	11	9
Selling, general & administrative	80	89	85	77	76	61	53	44	39	51	47	45
Other expenses	240	94	1	28	10	76	0	0	0	0	0	209
Operating income	−242	−44	40	−204	65	−10	49	1	77	−17	11	−125
	−24	−11	−28	−66	78	−18	44	−17	−19	−34	3	−41
Interest income	0	1	0	0	0	0	0	0	0	0	0	0
Interest expense	20	22	24	24	8	15	15	15	15	15	11	10
Other non-operating income	−239	−2	3	−44	−8	−5	−59	3	4	19	−14	31
Income before tax	−266	−55	12	−270	142	−28	93	−17	58	−51	13	−166
Income tax expense	−3	−5	3	13	28	4	25	−5	6	4	7	14
Net income from continuing operations	−263	−50	9	−283	115	−31	68	−12	51	−55	7	−180
Net income	−263	−50	9	−283	115	−31	68	−12	51	−55	7	−180
EPS, basic	−$5.13	−$0.95	$0.17	−$5.38	$2.16	−$0.59	$1.25	−$0.22	$0.96	−$1.04	$0.13	−$3.49
EPS, diluted	−$5.13	−$0.95	$0.17	−$5.38	$2.06	−$0.59	$1.19	−$0.22	$0.91	−$1.04	$0.07	−$3.49
Weighted average shares, basic	52	52	52	53	53	54	54	54	53	52	52	52
Weighted average shares, diluted	52	52	52	53	56	54	57	54	57	52	57	52
EBITDA	23	−14	63	−132	98	21	133	22	97	−13	49	−156
Depreciation & amortization	27	29	27	28	26	25	26	24	24	24	24	0
EBIT	−4	−42	36	−159	72	−4	107	−2	73	−36	24	−156